China Regenerative Medicine International (HKG:8158) First Half 2024 Results
Key Financial Results
- Revenue: HK$59.8m (down 40% from 1H 2023).
- Net income: HK$16.8m (up 32% from 1H 2023).
- Profit margin: 28% (up from 13% in 1H 2023). The increase in margin was driven by lower expenses.
- EPS: HK$0.055 (up from HK$0.045 in 1H 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
China Regenerative Medicine International's share price is broadly unchanged from a week ago.
Risk Analysis
Be aware that China Regenerative Medicine International is showing 2 warning signs in our investment analysis and 1 of those can't be ignored...
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.